Ligand Pharmaceuticals | LGND - Operating Expenses


Ligand Pharmaceuticals reported $8.29M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD -274.14M 80.46M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Baxter International USD 3.19B 554.4M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Enviri Corporation USD 590.29M 229.2M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.16B 558M Dec/2025
Pacira USD 193.68M 27.32M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 116M 7.24M Dec/2025